BiologicsRecon

Zimmer Acquires ETEX Holdings, Inc.

Zimmer Expands Portfolio of Early Intervention and Joint Preservation Solutions

WARSAW, Ind., Oct. 1, 2014 /PRNewswire/ — Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today that it has acquired the business of Cambridge, Massachusetts-based ETEX Holdings, Incorporated.  The financial terms of the transaction were not disclosed.  The acquisition enhances Zimmer’s Biologics portfolio of differentiated treatments through the addition of ETEX’s Beta-bsm™ (Injectable), CarriGen®, EquivaBone® (including DBM), and Gamma-bsm™ (Putty) bone void filler products.

“Since 1989, ETEX has been focused on Dosuk Lee’s vision of providing clinical solutions that advance the orthopaedic standard of care.  His breakthrough technology in biomimetic calcium phosphate, which mimics the chemical and structural features of human bone, promotes natural bone regeneration that positively impacts patients’ lives,” said Stephen R. La Neve, ETEX President and Chief Executive Officer.  “Zimmer’s long history, dedication and focus in the orthopaedic market is a perfect complement to our technology and dramatically expands our ability to reach a broader array of clinicians.”

“Zimmer is committed to developing the most comprehensive range of biologic therapies for patients suffering from musculoskeletal joint disease, from early intervention solutions like Gel-One®* Cross-linked Hyaluronate and joint preservation solutions like Zimmer Knee Creations Subchondroplasty® Procedure, along with Zimmer’s Chondrofix® Osteochondral Allograft and Denovo® NT Natural Tissue Graft personalized cartilage solutions.  ETEX’s innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease,” said Joseph A. Cucolo, President, Zimmer Americas.

*Gel-One is a registered trademark of Seikagaku Corporation.

About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer’s 2013 sales were approximately$4.6 billion.  The Company is supported by the efforts of more than 9,000 employees worldwide.  More information about Zimmer is available at www.zimmer.com.

About ETEX Holdings, Inc.
Established in 1989, ETEX Holdings, Inc. develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes.  A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems.  For more information, visit www.etexcorp.com.

Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management’s beliefs and assumptions made by management.  Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” and “seeks” or the negative of such terms or other variations on such terms or comparable terminology.  These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially.  For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this document.

Logo – http://photos.prnewswire.com/prnh/20131216/MM33947LOGO

SOURCE Zimmer Holdings, Inc.

 

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close